Review





Similar Products

programmed death 1  (Multi Sciences (Lianke) Biotech Co Ltd)
94
Multi Sciences (Lianke) Biotech Co Ltd programmed death 1
Programmed Death 1, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/programmed death 1/product/Multi Sciences (Lianke) Biotech Co Ltd
Average 94 stars, based on 1 article reviews
programmed death 1 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
anti pd 1 antibody  (MedChemExpress)
94
MedChemExpress anti pd 1 antibody
Anti Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pd 1 antibody/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anti pd 1 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
anti mouse pd 1 antibodies  (MedChemExpress)
94
MedChemExpress anti mouse pd 1 antibodies
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Anti Mouse Pd 1 Antibodies, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse pd 1 antibodies/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anti mouse pd 1 antibodies - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
anti mouse pd 1 antibody  (MedChemExpress)
94
MedChemExpress anti mouse pd 1 antibody
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Anti Mouse Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse pd 1 antibody/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anti mouse pd 1 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
αpd 1  (MedChemExpress)
95
MedChemExpress αpd 1
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
αpd 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/αpd 1/product/MedChemExpress
Average 95 stars, based on 1 article reviews
αpd 1 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
anti mouse pd l1 b7 h1 antibody  (MedChemExpress)
94
MedChemExpress anti mouse pd l1 b7 h1 antibody
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Anti Mouse Pd L1 B7 H1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse pd l1 b7 h1 antibody/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anti mouse pd l1 b7 h1 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
p99145  (MedChemExpress)
94
MedChemExpress p99145
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
P99145, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p99145/product/MedChemExpress
Average 94 stars, based on 1 article reviews
p99145 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
murine pd l1  (Sino Biological)
94
Sino Biological murine pd l1
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Murine Pd L1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine pd l1/product/Sino Biological
Average 94 stars, based on 1 article reviews
murine pd l1 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
anti mouse pd l1 pe  (Thermo Fisher)
94
Thermo Fisher anti mouse pd l1 pe
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Anti Mouse Pd L1 Pe, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse pd l1 pe/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
anti mouse pd l1 pe - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the anti-PD-1 group.

Journal: Materials Today Bio

Article Title: Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling

doi: 10.1016/j.mtbio.2025.102749

Figure Lengend Snippet: Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the anti-PD-1 group.

Article Snippet: Anti-mouse PD-1 antibodies (Cat. No. S-5001) were obtained from MedChemExpress.

Techniques: Inhibition, Activation Assay, Flow Cytometry, Expressing